-
Innovation Ranking
NewInnovation Ranking – Cogent Biosciences Inc
Cogent Biosciences Inc (Cogent Biosciences) formerly, Unum Therapeutics Inc is a clinical-stage biopharmaceutical company that develops and commercializes precision therapies for genetically defined diseases. The company's pipeline product portfolio includes CGT9486 which is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis, a serious disease caused by the unchecked proliferation of mast cells....
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Bezuclastinib in Gastrointestinal Stromal Tumor (GIST)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bezuclastinib in Gastrointestinal Stromal Tumor (GIST) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bezuclastinib in Gastrointestinal Stromal Tumor (GIST) Drug Details: Bezuclastinib...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Bezuclastinib in Systemic Mastocytosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bezuclastinib in Systemic Mastocytosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bezuclastinib in Systemic Mastocytosis Drug Details: Bezuclastinib (CGT-9486) is under development for...
-
Product Insights
Gastrointestinal Stromal Tumor (GIST) – Drugs In Development, 2023
Global Markets Direct’s, ‘Gastrointestinal Stromal Tumor (GIST) - Drugs In Development, 2023’, provides an overview of the Gastrointestinal Stromal Tumor (GIST) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gastrointestinal Stromal Tumor (GIST), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Mesenchymal Tumor Of The Gastrointestinal Tract – Drugs In Development, 2023
Global Markets Direct’s, ‘Mesenchymal Tumor Of The Gastrointestinal Tract - Drugs In Development, 2023’, provides an overview of the Mesenchymal Tumor Of The Gastrointestinal Tract pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mesenchymal Tumor Of The Gastrointestinal Tract, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Hypersecretory Conditions – Drugs In Development, 2023
Global Markets Direct’s, ‘Hypersecretory Conditions - Drugs In Development, 2023’, provides an overview of the Hypersecretory Conditions pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hypersecretory Conditions, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Systemic Mastocytosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Systemic Mastocytosis - Drugs In Development, 2023’, provides an overview of the Systemic Mastocytosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Systemic Mastocytosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Mast Cell Leukemia – Drugs In Development, 2023
Global Markets Direct’s, ‘Mast Cell Leukemia - Drugs In Development, 2023’, provides an overview of the Mast Cell Leukemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mast Cell Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Mesenchymal Tumor – Drugs In Development, 2023
Global Markets Direct’s, ‘Mesenchymal Tumor - Drugs In Development, 2023’, provides an overview of the Mesenchymal Tumor pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mesenchymal Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Net Present Value Model: Cogent Biosciences Inc’s Bezuclastinib
Empower your strategies with our Net Present Value Model: Cogent Biosciences Inc's Bezuclastinib report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.